Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.
Nasopharyngeal CarcinomaRecurrent Nasopharyngeal Carcinoma3 moreThis is an open-label, single center, pilot trial to evaluate the safety and efficacy of toripalimab and gemcitabine in patients with recurrent or metastatic nasopharyngeal carcinoma.
Itacitinib in Advanced Hepatocellular Carcinoma
Advanced Hepatocellular CarcinomaThis research will assess the effects of Itacitinib as a second line treatment for patients with advanced inflammatory hepatocellular carcinoma (HCC), a type of liver cancer. Itacinib is a protein inhibitor of the tyrosine kinase, JAK1, which is believed to enable cancer cells to metastasise to other parts of the body.
Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer...
Breast CancerRenal Cell CarcinomaMARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma, in combinations with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple negative breast cancer (TNBC) and in combination with Tecentriq and Avastin (bevacizumab) in front-line renal cell cancer (RCC).
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for...
Biliary Tract CarcinomaThis is a study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma. The primary hypothesis is pembrolizumab plus gemcitabine/cisplatin is superior to placebo plus gemcitabine/cisplatin with respect to overall survival (OS).
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
Clear Cell Renal Cell CarcinomaRenal Cell Carcinoma1 moreThis phase II clinical trial studies how well cabozantinib works in treating patients with kidney cancer before surgery. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian...
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian Carcinoma7 moreThis trial studies the side effects and best dose of AVB-S6-500 when given together with durvalumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum therapy or has come back. Immunotherapy with AVB-S6-500 and durvalumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
Metastatic Renal Cell CarcinomaFumarate Hydratase Deficient Renal Cell Carcinoma1 moreThe purpose of this study is to see whether the combination of avelumab and talazoparib can be an effective treatment for metastatic renal cell carcinoma.
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS...
Advanced Microsatellite Stable Colorectal CancerMetastatic Microsatellite-stable Colorectal CancerThe purpose of this study is to evaluate the efficacy and safety of sintilimab and chidamide in combination with or without IBI305(bevacizumab) in patients with standard treatment failure of advanced or metastatic pMMR/MSS colorectal adenocarcinoma.
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal...
Basal Cell CarcinomaThis phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with Basal Cell Carcinoma (BCC). Goals: To determine the safe and effective recommended dose of STP705 for the treatment of basal cell carcinoma. Analysis of biomarkers common to BCC formation pathway including TGF-β1 and COX-2.
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine...
Lung Small Cell CarcinomaNeuroendocrine Carcinoma4 moreThis phase II trial studies the effect of niraparib and dostarlimab in treating small cell lung cancer and other high-grade neuroendocrine carcinomas. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as dostarlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving niraparib and dostarlimab may help to control the diseases.